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https://doi.org/10.1186/s12882-019-1611-8RESEARCH ARTICLE Open AccessEfficacy and safety of sodium zirconium
cyclosilicate in patients with baseline serum
potassium level ≥ 5.5 mmol/L: pooled
analysis from two phase 3 trials
Alpesh N. Amin1*, Jose Menoyo2, Bhupinder Singh1,2 and Christopher S. Kim3Abstract
Background: Reliable, timely-onset, oral treatments with an acceptable safety profile for patients with hyperkalemia
are needed. We examined the efficacy and safety of sodium zirconium cyclosilicate (SZC; formerly ZS-9) treatment
for ≤ 48 h in patients with baseline serum potassium level ≥ 5.5 mmol/L.
Methods: Data were pooled from two phase 3 studies (ZS-003 and HARMONIZE) among patients receiving SZC
10 g three times daily. Outcomes included mean and absolute change from baseline, median time to potassium
level ≤ 5.5 and ≤ 5.0 mmol/L, and proportion achieving potassium level≤ 5.5 and ≤ 5.0 mmol/L at 4, 24, and 48 h.
Outcomes were stratified by baseline potassium. Safety outcomes were evaluated.
Results: At baseline, 125 of 170 patients (73.5%) had potassium level 5.5–< 6.0, 39 (22.9%) had potassium level 6.0–6.5,
and 6 (3.5%) had potassium level > 6.5 mmol/L. Regardless of baseline potassium, mean potassium decreased at 1 h
post-initial dose. By 4 and 48 h, 37.5% and 85.0% of patients achieved potassium level≤ 5.0 mmol/L, respectively.
Median (95% confidence interval) times to potassium level≤ 5.5 and≤ 5.0mmol/L were 2.0 (1.1–2.0) and 21.6 (4.1–22.4) h,
respectively. Fifteen patients (8.8%) experienced adverse events; none were serious.
Conclusions: SZC 10 g three times daily achieved serum potassium reduction and normokalemia, with a favorable
safety profile.
Trial registration: ClinicalTrials.gov identifiers: ZS-003: NCT01737697 and HARMONIZE: NCT02088073.
Keywords: Efficacy, Hyperkalemia, Safety, Sodium zirconium cyclosilicateBackground
Hyperkalemia is a potentially life-threatening electrolyte
abnormality associated with poor clinical outcomes [1],
cardiac dysrhythmias [2], increased mortality [3–5], and
higher use of healthcare resources [1]. Despite the poten-
tial for devastating sequelae, the threshold for and means
of treating hyperkalemia vary in clinical practice [6].© The Author(s). 2019 Open Access This artic
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Full list of author information is available at the end of the articleHyperkalemia therapies (e.g., intravenous insulin and glu-
cose or inhaled β2 agonists) typically used in the emergency
department and other acute care settings to lower serum
potassium (K+) are temporary in nature and impractical for
ongoing outpatient use [6, 7]. Although acute dialysis may
be used in select patients for the immediate treatment of
hyperkalemia, this procedure is invasive and costly, presents
logistical challenges, and may require an inpatient admis-
sion [7]. While nonspecific cation-exchange resins (e.g.,
sodium polystyrene sulfonate [SPS] and patiromer) are ad-
equately suited for the outpatient setting, they have been
associated with questionable tolerability [8, 9] or a slow
onset of action [6, 8, 10]. Therefore, there remains a need
for more reliable treatment options for patients with hyper-
kalemia that allow for rapid and safe reduction of K+ values.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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is an oral, nonabsorbed, high-capacity cation-binding
compound that selectively exchanges K+ for hydrogen
and sodium ions throughout the gastrointestinal tract
[11]. SZC is thought to start binding potassium in the
upper gastrointestinal tract, which most likely accounts
for its rapid onset of action [11, 12] (AstraZeneca, un-
published observations). In clinical studies of patients
with hyperkalemia, SZC has been shown to reduce
serum K+ levels within 1 h of administration [7, 13–15].
SZC is currently approved for the treatment of patients
with hyperkalemia in the United States (US) and the
European Union. The current analysis examined the
efficacy and safety of SZC for up to 48 h among patients
with moderate to severe hyperkalemia (baseline serum
K+ level ≥ 5.5 mmol/L). These results may have potential
implications for treating patients with moderate to severe
hyperkalemia that is not immediately life-threatening.
Materials and methods
Design and setting
This post hoc analysis included data pooled from two
published, randomized, double-blind, phase 3 trials: ZS-
003 (ClinicalTrials.gov identifier: NCT01737697) and
HARMONIZE (NCT02088073). Primary safety and effi-
cacy data from both studies previously have been re-
ported [13, 15], and short-term findings of a subset of
data from this post hoc analysis previously have been
summarized [7]. Briefly, both trials enrolled patients to
receive SZC (ZS-003 also included a placebo arm) three
times daily (TID) for up to 48 h during the correction
phase, followed by once-daily maintenance dosing for
12 days (ZS-003) or 28 days (HARMONIZE) in an out-
patient setting. Both phase 3 studies were conducted in
accordance with Good Clinical Practice guidelines and
the provisions of the Declaration of Helsinki, and all pa-
tients provided written informed consent before study
participation.
Study population
Inclusion criteria for the pivotal phase 3 studies included
ambulatory patients aged ≥ 18 years. Patients were ex-
cluded from the studies if they were being treated as an in-
patient, undergoing dialysis, had a life expectancy of
< 3months, experienced cardiac dysrhythmia that re-
quired immediate treatment, or had received treatment
with K+-binding resins within 7 days. Patients selected for
this analysis had baseline serum K+ levels ≥ 5.5mmol/L
and received SZC 10 g TID for up to 48 h in the correc-
tion phase of either study. Patients were excluded from
the analysis if they had a baseline serum K+ level < 5.5
mmol/L or had received any other dose of SZC. The ana-
lysis population was further stratified by baseline serum
K+ level (5.5–< 6.0, 6.0–6.5, and > 6.5 mmol/L).Interventions and study outcomes
All patients received SZC 10 g TID with meals for 48 h.
SZC was administered as a tasteless, odorless, white
powder mixed with water. On study day 1, SZC was ad-
ministered before breakfast, and with meals for the re-
mainder of both studies. Patients were maintained on
their usual medications throughout each study, including
diuretic agents, renin–angiotensin–aldosterone system
inhibitor (RAASi) therapies, and glucose-lowering treat-
ments. Patients were not subjected to dietary restrictions
and were instructed to maintain their usual diet without
specified alterations.
In both trials, K+ levels were measured at 0, 1, 2, 4, 24,
25, and 48 h following the first dose of SZC, with the 0-,
1-, and 2-h measurements occurring before breakfast on
day 1. K+ levels were measured through point-of-care
testing using an i-STAT device (Abbott Point of Care,
Inc.; Princeton, NJ, USA) for immediate treatment deci-
sions and via the central laboratory (referred to as serum
K+) for the assessment of primary and secondary out-
comes, as previously described [13, 15]. Outcomes of
interest for the current analysis included mean serum
and i-STAT K+ levels over time; absolute change from
baseline in serum and i-STAT K+ levels; median time to
serum and i-STAT K+ levels of ≤ 5.5, ≤ 5.1, and ≤ 5.0
mmol/L; proportions of patients achieving serum and i-
STAT K+ levels of ≤ 5.5, ≤ 5.1, and ≤ 5.0 mmol/L at 4, 24,
and 48 h; and safety data (including adverse events [AEs]
and serum laboratory data).
Statistical analysis
Descriptive statistics were provided for all categorical
outcomes. Statistical analyses were based on serum K+
levels as measured by the central laboratory. Paired t
tests were used to evaluate the change from baseline in
serum K+ and laboratory parameters. Kaplan-Meier life
tables were used to estimate the time to serum K+ and i-
STAT K+ levels of ≤ 5.5, ≤ 5.1, and ≤ 5.0 mmol/L and are
presented as median ± 95% confidence interval (CI). The
95% CI for the median time to normalization was calcu-
lated with distribution-free assumption nonparametric
method. Patients who did not meet the K+ level goals
were censored for the analysis on the last treatment day
during the correction phase. For any missing time meas-
urement from the database for analyses of i-STAT K+
time to achievement of K+ goals, the nominal time point
for that patient was used for calculations. Safety data
were summarized as incidence (number and percentage
of patients).
Results
Baseline demographics and characteristics
Of the 401 patients who received SZC 10 g TID for up
to 48 h during the correction phase of the two phase 3
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≥ 5.5 mmol/L. Baseline demographic and clinical data
are summarized in Table 1. Most patients were male
(61.8%), with a mean (standard deviation) age of 65.7
(12.1) years. There was a high burden of comorbidities
in this patient population, including chronic kidney dis-
ease, congestive heart failure, and diabetes mellitus.Table 1 Baseline demographics and characteristics of patients
with baseline serum K+ ≥ 5.5 mmol/L
Parameter Overall
(N = 170)
Age, years, mean (SD) 65.7 (12.1)
Male, n (%) 105 (61.8)
Race, n (%)
White 134 (78.8)
Black or African American 31 (18.2)
Asian 3 (1.8)
Other 2 (1.2)
Ethnicity, n (%)
Hispanic 44 (25.9)
Non-Hispanic 126 (74.1)
Serum K+, mmol/L, n (%) 170 (100.0)
5.5 to < 6.0 125 (73.5)
6.0 to 6.5 39 (22.9)
> 6.5 6 (3.5)
Serum K+, mmol/L, mean (95% CI) 5.8 (5.8–5.9)
5.5 to < 6.0 5.7 (5.7–5.7)
6.0 to 6.5 6.2 (6.1–6.2)
> 6.5 6.9 (6.6–7.2)
eGFR, mL/min/1.73 m2, n (%)
< 15 28 (16.5)
15 to < 30 55 (32.4)
30 to < 60 51 (30.0)
≥ 60 32 (18.8)
Missing 4 (2.4)
Comorbidity, n (%)a
Chronic kidney disease 113 (66.5)
Diabetes mellitus 112 (65.9)
Heart failure 22 (12.9)
Concomitant medications, n (%) 167 (98.2)
RAASi 113 (66.5)
Diuretics 78 (45.9)
β-blockers 77 (45.3)
Medications received, mean (SD) 8.7 (4.5)
CI confidence interval, eGFR estimated glomerular filtration rate, K+ potassium,
RAASi renin–angiotensin–aldosterone system inhibitor, SD standard deviation
aAs defined by standardized Medical Dictionary for Regulatory Activities query
narrow termsNearly all patients were taking concomitant medications
at baseline (98.2%). The most common medications were
RAASi therapies (66.5%), followed by diuretics (45.9%)
and β-blockers (45.3%). The mean (standard deviation)
number of medications per patient was 8.7 (4.5).
Of the 170 patients with a baseline serum K+ level
≥ 5.5 mmol/L included in this analysis, the mean serum
K+ level at baseline was 5.83 (95% CI, 5.78–5.88) mmol/L.
Most patients (n = 125 [73.5%]) had a baseline serum
K+ level 5.5–< 6.0mmol/L, with a mean serum K+ level of
5.68 (95% CI, 5.65–5.70) mmol/L. Thirty-nine patients
had a baseline serum K+ level of 6.0–6.5mmol/L (mean
[95% CI], 6.18 [6.13–6.24] mmol/L), and 6 patients had a
baseline serum K+ level of > 6.5mmol/L (mean [95% CI],
6.87 [6.59–7.15] mmol/L).
Efficacy outcomes
Treatment with SZC 10 g TID in the correction phase re-
sulted in a reduction from baseline in mean serum K+ levels
in the overall population and in all serum K+ subgroups
(Fig. 1). In the overall population, serum K+ levels de-
creased as early as 1 h after the first dose of SZC 10 g (mean
[95% CI], −0.27 [−0.34 to −0.21]; p < 0.001 vs. baseline).
Similar results were observed in the 5.5–< 6.0 and 6.0–6.5
mmol/L subgroups (p ≤ 0.001 for all comparisons vs. base-
line). Patients in the > 6.5mmol/L subgroup experienced a
change from baseline in serum K+ levels of −0.83mmol/L
by 2 h post dose (p < 0.05 vs. baseline). By 4 h post dose,
changes from baseline in serum K+ levels of −0.55, −0.70,
and −0.82mmol/L were observed in the 5.5–< 6.0, 6.0–6.5,
and > 6.5mmol/L subgroups, respectively (p ≤ 0.01 for all
comparisons vs. baseline). Mean serum K+ levels were de-
creased by 48 h after the initial dose in all baseline K+ strata
(Fig. 1). Patients with baseline serum K+ level > 6.5mmol/L
experienced the largest reduction in serum K+ levels by 48
h (−1.90mmol/L; p < 0.01 vs. baseline). Similar results were
observed when i-STAT K+ levels were examined over time
in the overall population and in all baseline serum K+ strata
(Additional file 1: Figure S1).
A serum K+ level of ≤ 5.5 mmol/L was achieved by
66% of patients within 2 h of initial treatment with SZC
10 g, and nearly 80 and 98% of patients achieved this
serum K+ level within 4 and 48 h, respectively (Fig. 2a).
A serum K+ level of ≤ 5.0 mmol/L was achieved by more
than one-third (38%) of patients by 4 h after the initial
dose of SZC 10 g, and 85% of patients achieved this serum
K+ level at 48 h (Fig. 2b). Data for the proportions of pa-
tients who achieved a serum K+ level of ≤ 5.1mmol/L are
presented in Additional file 2: Figure S2. In general, simi-
lar proportions of patients achieved i-STAT K+ goals over
time in the overall population and in all baseline serum
K+ strata (Additional file 3: Figure S3).
The median time to a serum K+ level of ≤ 5.5mmol/L in
the overall population was 2.0 (95% CI, 1.1–2.0) h (Table 2).
Fig. 1 Mean (95% CI) serum K+ over time. CI, confidence interval; K+, potassium. *p≤ 0.001; †p < 0.01; ‡p < 0.05 for absolute change from baseline
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to ≤ 5.0mmol/L was 21.6 (95% CI, 4.1–22.4) h. Although
patients with higher baseline serum K+ levels experienced
longer median times to normalization than patients
with lower serum K+ levels, all but one patient with
baseline serum K+ level of > 6.5mmol/L achieved serum
K+ ≤ 5.5mmol/L within 48 h (median time [95% CI], 20.6
[2.2–24.3] h). The median time to achievement of serum
K+ level ≤ 5.1mmol/L is presented in Additional file 4:
Table S1. When examining the time to achievement of i-
STAT K+ levels ≤ 5.5, ≤ 5.1, and ≤ 5.0mmol/L, it was found
that i-STAT K+ goals were achieved in less time than
serum K+ goals (Additional file 5: Table S2).Safety
AEs were observed in 15 patients (8.8%) with baseline
serum K+ level of ≥ 5.5 mmol/L during the first 48 h of
treatment (Table 3). Most AEs were gastrointestinal-
related disorders (5 patients [2.9%]). No serious AEs
were reported during the correction phase.At 48 h, no cases of hypokalemia (serum K+ level < 3.5
mmol/L), 1 case (0.6%) of hypocalcemia (< 1.8 mmol/L),
and 3 new cases (27.3%) of hypomagnesemia (< 0.6
mmol/L) were observed. Changes from baseline to 48 h
were observed for mean magnesium, calcium, and bicar-
bonate (Additional file 6: Table S3).
Discussion
This post hoc analysis demonstrated that SZC reduces
serum K+ levels in patients with baseline serum K+
levels of ≥ 5.5 mmol/L. Furthermore, in this patient
population, a single treatment with SZC 10 g reduced
serum K+ levels at 1 h after the initial dose. Treat-
ment with SZC 10 g TID resulted in a continued and
sustained reduction in serum K+ levels for up to 48 h
after the initial dose. These trends held true for all
baseline serum K+ strata. In addition, SZC 10 g dem-
onstrated a safety profile consistent with that ob-
served in prior studies [13, 15].
A single-dose treatment with SZC 10 g reduced mean
serum K+ levels within 1 h of the initial dose by 0.27
Fig. 2 Patients with serum potassium (K+) levels (a) ≤ 5.5 mmol/L and (b) ≤ 5.0 mmol/L at various time points
Table 2 Median time to achievement of serum K+ levels ≤ 5.5 and≤ 5.0 mmol/L in the correction phase
Median (95% CI) time
to serum K+ level,
hours
Overall
(N = 170)
Baseline Serum K+ level (mmol/L)
5.5–< 6.0
(n = 125)
6.0–6.5
(n = 39)
> 6.5
(n = 6)
Serum K+≤ 5.5 mmol/L 1.97 (1.08–2.00) 1.08 (1.03–1.97) 3.97 (2.00–19.63) 20.55 (1.00–47.97)
Serum K+≤ 5.0 mmol/L 21.55 (4.08–22.42) 4.22 (4.00–21.92) 23.50 (20.85–45.27) 45.30 (1.00–48.70)
CI confidence interval, K+ potassium
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Table 3 AEs and SAEs in patients who received SZC 10 g in the pooled correction phase
Parameter, n (%) Overall
(N = 170)
Baseline Serum K+ level (mmol/L)
5.5–< 6.0
(n = 125)
6.0–6.5
(n = 39)
> 6.5
(n = 6)
Any AEsa 15 (8.8) 7 (5.6) 8 (20.5) 0 (0.0)
Gastrointestinal disorders 5 (2.9) 2 (1.6) 3 (7.7) 0 (0.0)
Constipation 3 (1.8) 1 (0.8) 2 (5.1) 0 (0.0)
Diarrhea 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Peripheral edema 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Upper respiratory tract infection 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Blood glucose decreased 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Headache 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Cough 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Ecchymosis 1 (0.6) 0 (0.0) 1 (2.6) 0 (0.0)
Serious AEs 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
AE adverse event, K+ potassium, SAE serious adverse event, SZC sodium zirconium cyclosilicate
aAny AE that occurred in > 2% of patients, regardless of relation to study drug. Bold text indicates total number of events
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mmol/L. In general, the most marked reductions in
serum K+ levels were observed in patients with the high-
est serum K+ level at baseline in previous studies [13],
which was confirmed in the present analysis. Nearly
two-thirds (65.5%) of all patients with moderate to se-
vere hyperkalemia achieved serum K+ level ≤ 5.1 mmol/L
within 24 h in the present study, which was achieved by
84% of the overall patient population in the same time
period in the HARMONIZE trial [13]. This trend was
further reflected in the median time to serum K+ level
≤ 5.0 mmol/L, where patients in the overall population
of the HARMONIZE trial demonstrated normalized
serum K+ levels in 2.2 h [13]. This corresponded with a
median time of 21.6 h in the current analysis, which is
expected for a patient population with a higher mean
baseline serum K+ level than that observed in the
HARMONIZE trial.
In the current analysis, a single dose of SZC 10 g
resulted in most patients (79%) with a baseline K+
level ≥ 5.5 mmol/L achieving a serum K+ level ≤ 5.5
mmol/L, and more than one-third (38%) of all pa-
tients achieving a K+ level ≤ 5.0 mmol/L within 4 h.
These results are consistent with those from an earl-
ier pooled analysis of the same two trials assessing
patients with a slightly higher baseline serum K+
threshold (≥ 6.0 mmol/L), which found that 52% of
patients achieved a serum K+ level ≤ 5.5 mmol/L by
4 h after the first SZC 10 g dose [7]. Considering the
mean baseline serum K+ level in the previous
analysis was 6.3 mmol/L, it is not unexpected that
fewer patients in that analysis were able to achieve
normalization rates comparable to that seen in the
current analysis at 4 h.The safety profile of SZC 10 g TID demonstrated in
the current patient population was generally consistent
with that observed in the overall populations who re-
ceived SZC during the two phase 3 trials [13, 15]. The
most common AEs experienced by patients in this ana-
lysis were gastrointestinal-related disorders (2.9%), with
constipation being the most frequent gastrointestinal AE
(1.8%). In the HARMONIZE study, the most common
AE was edema [12], and in the ZS-003 study, the most
common AE in both placebo and SZC treatment groups
was diarrhea [14].
The clinical and economic burden of hyperkalemia is
well known. In a recent analysis of the cost of hyperka-
lemia in the United States (N = 39,626 patients with
hyperkalemia and an equal number of matched
controls), patients with hyperkalemia incurred $4128
higher 30-day healthcare costs than matched controls
($5994 vs. $1866, respectively) [16]. A review of
911,698 medical records across the US demonstrated
that, in the absence of known cardiovascular disease,
diabetes, heart failure, or chronic kidney disease, mor-
tality was shown to be 7.5-fold higher in individuals
with K+ levels of 5.5–8.0 mmol/L vs. those with K+
levels of 4.0–< 5.0 mmol/L [17]. In a cohort study of
more than 55,000 patients with chronic kidney disease
not undergoing dialysis, serum K+ levels of ≥ 6.0 mmol/
L were associated with a higher risk of death, major ad-
verse cardiovascular events, hospitalizations, and dis-
continuations of RAASi therapy [1]. Elevated K+ was
the cause of approximately 67,000 visits to US emer-
gency departments during 2011, with 50% of these
visits resulting in hospital admissions [18]. The average
length of stay associated with a hyperkalemia admission
was 3.2 days, with an estimated cost of $24,178. Among
Amin et al. BMC Nephrology          (2019) 20:440 Page 7 of 8Medicare beneficiaries, total annual hospital expendi-
tures for admissions with hyperkalemia as the primary
diagnosis totaled nearly $700 million [18]. More recent
US data in 2014 demonstrated that patients admitted
with a primary diagnosis of hyperkalemia accrued an
average length of stay of 3.3 days and a mean cost of
$29,181 per stay, for an estimated total annual hospital
charge of $1.2 billion [19]. New hyperkalemia treatment
options may have the potential to positively impact
healthcare resource utilization.
Orally available therapeutic options for hyperkalemia,
including cation-binding compounds to eliminate K+,
have been in use since the late 1950s [20]. SPS and patir-
omer are the only other K+-binding resins currently ap-
proved for clinical use in the United States. However,
there is limited evidence to support their efficacy and
safety in the acute treatment of patients with serum K+
level ≥ 5.5 mmol/L. SPS was approved for use in the
United States in the absence of robust clinical trial evi-
dence to support drug efficacy [20, 21]. SPS has a slow
onset of action [10, 20] and poor predictability in its
ability to decrease serum K+ levels, and is, therefore, not
indicated for the acute treatment of severe hyperkalemia
[22]. In addition, SPS and patiromer have been associ-
ated with gastrointestinal-related AEs [8, 22–24].
There are several limitations of this study. This post hoc
analysis lacked a placebo control and included a limited
number of patients with a serum K+ level ≥ 6.0mmol/L
(n = 45). The phase 3 studies were performed in an out-
patient population, which may have limited the number of
patients with more severe hyperkalemia. The current ana-
lysis focused only on the correction phase of treatment.
While both phase 3 studies included maintenance-phase
treatment periods, those data could not be pooled for add-
itional analysis because of differences in study designs.
Further studies in the acute setting (e.g. emergency de-
partment and the hospital), in patients undergoing dialy-
sis, and those that evaluate the impact of treatment on
readmission rates are merited. Additional studies that
evaluate follow-up care and the ability to safely maintain
K+ values after acute care management are also warranted.
Given the mechanism of action of SZC, we do not expect
a difference in the treatment response between men and
women. Further analysis would need to be carried out to
verify this more formally.
Conclusions
Patients with baseline serum K+ level ≥ 5.5 mmol/L who
received SZC 10 g experienced decreases in serum K+
levels from baseline within 1 h of treatment, and most
patients (85%) who received SZC 10 g TID achieved nor-
mokalemia within 48 h. The reduction of serum K+
levels among patients with serum K+ level ≥ 5.5 mmol/L
with SZC was achieved with an acceptable safety profile,consistent with that observed in prior studies. These re-
sults may be of particular interest to hospitalists, obser-
vation/short-stay unit providers, and urgent care and
emergency department providers, who may see patients
with hyperkalemia and are uncertain about their clinical
trajectory. These patients are currently observed in these
settings for variable periods of time at a high cost, and
the results of this analysis may help guide the treatment
and transition plans for these patients.
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